組蛋白去乙醯酵素3 (SMAP45或EC 184.108.40.206) :開發中產品分析
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 220.127.116.11) - Drugs In Development, 2021
|出版商||Global Markets Direct||商品編碼||364840|
|出版日期||內容資訊||英文 124 Pages
|組蛋白去乙醯酵素3 (SMAP45或EC 18.104.22.168) :開發中產品分析 Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 22.214.171.124) - Drugs In Development, 2021|
|出版日期: 2021年08月31日||內容資訊: 英文 124 Pages||
本報告提供以組蛋白去乙醯酵素3 (SMAP45或EC 126.96.36.199) 為標的之治療藥開發相關資訊，提供您開發階段，藥物標的，作用機制，給藥途徑及各分子類型分析，開發治療藥的企業概要，最新消息和新聞稿等資訊。
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 188.8.131.52) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 3 - Drugs In Development, 2021, outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 220.127.116.11) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4, 1 and 10 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Melanoma, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Glioblastoma Multiforme (GBM), HER2- Breast Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Mycosis Fungoides, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Transitional Cell Cancer (Urothelial Cell Cancer), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anal Cancer, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bladder Cancer, Bone Disorders, Cervical Cancer, CNS Lymphoma, Colon Cancer, Cutaneous T-Cell Lymphoma, Drug Addiction, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Merkel Cell Carcinoma, Metastatic Breast Cancer, Myelodysplastic Syndrome, Natural Killer Cell Lymphomas, Neuroblastoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Peripheral T-Cell Lymphomas (PTCL), Post-Traumatic Stress Disorder (PTSD), Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma, Unspecified B-Cell Lymphomas, Ureter Cancer, Urethral Cancer and Vulvar Cancer.
Furthermore, this report also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 18.104.22.168) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.